Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, the companies also are investing in other ways to reduce their exposure to 340B program sales, which a major industry consulting firm says have been growing on average by 25 percent per year since 2014.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga